PsiOxus Therapeutics has posted topline data from a recently completed Phase II trial of MT-102 in cancer-related cachexia. The primary endpoint has been met, showing that patients treated with MT-102 during a 16-week period have greater weight gain when compared to placebo treated patients, and at the highest dose of MT-102 (10mg twice daily) the difference is statistically significant. The clinical study has thus demonstrated MT-102’s ability to halt the cycle of weight loss, weakness and fati...